CN104039952A - 用于树突状细胞癌症疫苗的小分子增强剂 - Google Patents

用于树突状细胞癌症疫苗的小分子增强剂 Download PDF

Info

Publication number
CN104039952A
CN104039952A CN201280067478.5A CN201280067478A CN104039952A CN 104039952 A CN104039952 A CN 104039952A CN 201280067478 A CN201280067478 A CN 201280067478A CN 104039952 A CN104039952 A CN 104039952A
Authority
CN
China
Prior art keywords
cancer
compound
cell
mammals
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280067478.5A
Other languages
English (en)
Chinese (zh)
Inventor
W.W.巴乔夫钦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Priority to CN201610493117.7A priority Critical patent/CN106075450A/zh
Publication of CN104039952A publication Critical patent/CN104039952A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Epoxy Compounds (AREA)
CN201280067478.5A 2011-11-22 2012-11-15 用于树突状细胞癌症疫苗的小分子增强剂 Pending CN104039952A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610493117.7A CN106075450A (zh) 2011-11-22 2012-11-15 用于树突状细胞癌症疫苗的小分子增强剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161562497P 2011-11-22 2011-11-22
US61/562,497 2011-11-22
PCT/US2012/065236 WO2013078059A1 (en) 2011-11-22 2012-11-15 Small molecule enhancer for dendritic cell cancer vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610493117.7A Division CN106075450A (zh) 2011-11-22 2012-11-15 用于树突状细胞癌症疫苗的小分子增强剂

Publications (1)

Publication Number Publication Date
CN104039952A true CN104039952A (zh) 2014-09-10

Family

ID=48470210

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280067478.5A Pending CN104039952A (zh) 2011-11-22 2012-11-15 用于树突状细胞癌症疫苗的小分子增强剂
CN201610493117.7A Pending CN106075450A (zh) 2011-11-22 2012-11-15 用于树突状细胞癌症疫苗的小分子增强剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610493117.7A Pending CN106075450A (zh) 2011-11-22 2012-11-15 用于树突状细胞癌症疫苗的小分子增强剂

Country Status (9)

Country Link
US (3) US9284337B2 (https=)
EP (2) EP2782994B1 (https=)
JP (2) JP6240083B2 (https=)
CN (2) CN104039952A (https=)
AU (2) AU2012340887A1 (https=)
CA (1) CA2856379A1 (https=)
HK (1) HK1201871A1 (https=)
IL (1) IL232664A0 (https=)
WO (1) WO2013078059A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108136025A (zh) * 2015-07-16 2018-06-08 比奥克斯塞尔医疗股份有限公司 一种使用免疫调节治疗癌症的新颖方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104039952A (zh) * 2011-11-22 2014-09-10 塔夫茨大学信托人 用于树突状细胞癌症疫苗的小分子增强剂
EP3224263B1 (en) 2014-11-25 2023-05-17 BioXcel LLC Use of ubiquitin-proteasome system inhibitors for treatment of tumors associated with neurofibromatosis type-2
WO2017020974A1 (en) * 2015-08-03 2017-02-09 Institut Pasteur Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
WO2018049014A1 (en) * 2016-09-07 2018-03-15 Trustees Of Tufts College Dash inhibitors, and uses related thereto
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
WO2018187698A2 (en) * 2017-04-07 2018-10-11 Trustees Of Tufts College Combination therapies using caspase-1 dependent anticancer agents and pge2 antagonists
US11559537B2 (en) 2017-04-07 2023-01-24 Trustees Of Tufts College Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists
JP2019208422A (ja) * 2018-06-04 2019-12-12 コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー ヒアルロニダーゼを含む新規な組換えエキソソーム及びその用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1607247A (zh) * 2003-10-15 2005-04-20 上海海欣生物技术有限公司 树突状细胞肿瘤疫苗及其制法和用途
WO2007123686A2 (en) * 2006-03-31 2007-11-01 Point Therapeutics, Inc. Dpp inhibitors and uses thereof
US20090124559A1 (en) * 2005-12-19 2009-05-14 Trustees Of Tufts College Office Of Technology And Industry Collaboration Soft Protease Inhibitors and Pro-Soft Forms Thereof
CN101755045A (zh) * 2007-05-17 2010-06-23 生物载体株式会社 树突状细胞的制备方法
CN101932707A (zh) * 2008-01-31 2010-12-29 库瑞瓦格有限责任公司 作为免疫刺激剂/佐剂的式(I)(NuGlXmGnNv)a的核酸及其衍生物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040145A (en) * 1997-05-07 2000-03-21 Tufts University Potentiation of the immune response
EP1104293A1 (en) 1998-08-21 2001-06-06 Point Therapeutics, Inc. Regulation of substrate activity
EP1187619A1 (en) * 1999-05-25 2002-03-20 Point Therapeutics, Inc. Anti-tumor agents comprising boroproline compounds
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
KR20080030079A (ko) * 2005-07-05 2008-04-03 트러스티즈 오브 터프츠 칼리지 섬유아세포 활성 단백질 알파의 억제제
WO2008116054A1 (en) * 2007-03-20 2008-09-25 Trustees Of Tufts College Inhibitors of fibroblast activation protein, and methods of use thereof
CN104039952A (zh) * 2011-11-22 2014-09-10 塔夫茨大学信托人 用于树突状细胞癌症疫苗的小分子增强剂

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1607247A (zh) * 2003-10-15 2005-04-20 上海海欣生物技术有限公司 树突状细胞肿瘤疫苗及其制法和用途
US20090124559A1 (en) * 2005-12-19 2009-05-14 Trustees Of Tufts College Office Of Technology And Industry Collaboration Soft Protease Inhibitors and Pro-Soft Forms Thereof
WO2007123686A2 (en) * 2006-03-31 2007-11-01 Point Therapeutics, Inc. Dpp inhibitors and uses thereof
CN101755045A (zh) * 2007-05-17 2010-06-23 生物载体株式会社 树突状细胞的制备方法
CN101932707A (zh) * 2008-01-31 2010-12-29 库瑞瓦格有限责任公司 作为免疫刺激剂/佐剂的式(I)(NuGlXmGnNv)a的核酸及其衍生物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SIMON J.COUTTS ET AL: "STRUCTURE-ACTIVITY RELATIONSHIPS OF BORONIC ACID INHIBITORS OF DIPEPTIDYL PEPTIDASE IV.1.VARIATION OF THE P2 POSITION OF Xaa-BOROPRO DIPEPTIDES", 《J.MED.CHEM》 *
THUY TRAN ET AL: "SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIP OF N-ACYL-GLY-,N-ACYL-SAR- AND N-BLOCKED-BOROPRO INHIBITORS OF FAP,TPP4，AND POP", 《BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108136025A (zh) * 2015-07-16 2018-06-08 比奥克斯塞尔医疗股份有限公司 一种使用免疫调节治疗癌症的新颖方法
CN116059218A (zh) * 2015-07-16 2023-05-05 比奥克斯塞尔医疗股份有限公司 一种使用免疫调节治疗癌症的新颖方法

Also Published As

Publication number Publication date
EP2782994A1 (en) 2014-10-01
JP2017214420A (ja) 2017-12-07
AU2012340887A1 (en) 2014-07-03
US20160310513A1 (en) 2016-10-27
EP2782994A4 (en) 2015-07-15
JP2014533727A (ja) 2014-12-15
EP2782994B1 (en) 2017-05-10
JP6240083B2 (ja) 2017-11-29
US20140271725A1 (en) 2014-09-18
CA2856379A1 (en) 2013-05-30
US9284337B2 (en) 2016-03-15
HK1201871A1 (en) 2015-09-11
US9839646B2 (en) 2017-12-12
EP3106173A1 (en) 2016-12-21
WO2013078059A1 (en) 2013-05-30
IL232664A0 (en) 2014-07-31
AU2018204591A1 (en) 2018-07-12
CN106075450A (zh) 2016-11-09
US20180092933A1 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
CN104039952A (zh) 用于树突状细胞癌症疫苗的小分子增强剂
US9295682B2 (en) Adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of clinical manifestations associated with diseases like cachexia and correction of adverse effects of drugs such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier specially selected and other substances with antineoplastic action and/or other treatments
RU2571551C1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
Ghiringhelli et al. Enhancing the anticancer effects of 5-fluorouracil: current challenges and future perspectives
US20170128477A1 (en) Composition for inhibiting myeloid-derived suppressor cells comprising decitabine or its pharmaceutically acceptable salt as active ingredient
CA2997671A1 (en) Combination therapies for treating cancer
NL2033623B1 (en) Use of lenvatinib plus anti-pd-1 monoclonal antibody in preparation of anti-hepatoma drug
KR20210152531A (ko) 종양을 치료하는 방법
WO2018053270A1 (en) Modified natural killer cells for the treatment of cancer
CN113440533A (zh) 水苏糖在制备用于治疗去势抵抗性前列腺癌药物中的应用
CN110664807B (zh) 一种具有协同抗黑色素瘤功效的药物组合物及其应用
CN104231047B (zh) 水溶性靶向激活的紫杉醇衍生物及其制备和用途
JP2022551672A (ja) 乳癌治療法
US11696904B2 (en) Prodrug for therapeutic applications
RU2813701C2 (ru) Способ угнетения роста меланомы у мышей-опухоленосителей
RU2524309C1 (ru) Способ выбора тактики лечения местно-распространенного рака предстательной железы
CN115282280A (zh) TGF-β1信号抑制剂的新用途
KR20070065311A (ko) 항암 치료 및 약제학적 조성물의 조합
HK1229708A1 (en) Small molecule enhancer for dendritic cell cancer vaccines
HK1229708A (en) Small molecule enhancer for dendritic cell cancer vaccines
JP2021533107A (ja) 癌を治療するための併用療法
RU2273502C1 (ru) Способ лечения рецидивов рака яичников
RU2597795C2 (ru) Ингибитор скопления жидкости в полостях организма
Gulyás Modification of the Innate Immune Response using Low Molecular Weight Substances and its Effect on Different Tumor Types
US20200030375A1 (en) Therapy and methods of introducing immature dendritic cells and/or cytoxic t lymphocyte and anti pd-1 / pd-l1 antibody for treatment of tumors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1201871

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140910

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1201871

Country of ref document: HK